Cytek Biosciences (CTKB): Evaluating Valuation After TIME's 2026 Growth Leaders Recognition and Recurring Revenue Momentum [Yahoo! Finance]
Cytek Biosciences, Inc. (CTKB)
Company Research
Source: Yahoo! Finance
This recognition highlights the company's continued innovation and business expansion, even as Q3 results showed modest growth. See our latest analysis for Cytek Biosciences. Momentum has sharply turned in Cytek's favor lately, with the share price jumping 39% over the past month as investors responded to industry accolades, product milestones, and steady full-year guidance. Short-term price gains stand in contrast to a 1-year total shareholder return of -8.8% and a significant 3-year total return decline. Recent buzz suggests sentiment is rebounding. If you're interested in what else is emerging in the sector, now is a perfect opportunity to explore the broader universe of innovators through our See the full list for free. With renewed investor enthusiasm and a double-digit share price rally, the question now becomes whether Cytek Biosciences is trading below its true value or if the market has already factored in future growth prospects. Most Popular Narrative: 7% Overvalu
Show less
Read more
Impact Snapshot
Event Time:
CTKB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTKB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTKB alerts
High impacting Cytek Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
CTKB
News
- Cytek Biosciences (NASDAQ:CTKB) was given a new $6.00 price target on by analysts at Morgan Stanley.MarketBeat
- Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth [Seeking Alpha]Seeking Alpha
- TIME Recognizes Cytek® Biosciences as One of America's Growth Leaders of 2026 [Yahoo! Finance]Yahoo! Finance
- TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026GlobeNewswire
- Cytek Biosciences (NASDAQ:CTKB) had its price target lowered by analysts at Piper Sandler from $8.00 to $7.50. They now have an "overweight" rating on the stock.MarketBeat
CTKB
Earnings
- 11/5/25 - Beat
CTKB
Sec Filings
- 11/20/25 - Form 4
- 11/20/25 - Form 4
- 11/20/25 - Form 4
- CTKB's page on the SEC website